Comparative Pharmacology
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus TOLECTIN 600.
MEPROBAMATE AND ASPIRIN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID / Antiplatelet
NSAID